Barinthus Biotherapeutics (BRNS) Cash from Operations (2020 - 2026)
Barinthus Biotherapeutics (BRNS) reported Cash from Operations of 3366000.0 for Q1 2026, up 77.41% on a YoY basis from 1897274.08 in Q1 2025, and up 20.65% quarter-over-quarter from 4242000.0 in Q4 2025.
Barinthus Biotherapeutics (BRNS) Cash from Operations (2020 - 2026) Analysis & Trends
Barinthus Biotherapeutics has reported Cash from Operations for 7 years, with the latest figure at 3366000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Operations rose 77.41% year-over-year to 3366000.0; the trailing twelve-month figure through Mar 2026 stood at 36443000.0 (down 13.81% YoY), and the FY2025 full-year result was 47979000.0, down 65.79% from the prior year.
- Cash from Operations for Q1 2026 stood at 3366000.0, up from 4242000.0 in the prior quarter.
- The five-year high for Cash from Operations was 13086000.0 in Q4 2024, with the low at 19603000.0 in Q4 2023.
- Historically, Cash from Operations has averaged 8567117.65 across 5 years, with a median of 11191000.0 in 2023.
- Annual changes were most pronounced in 2022 — Cash from Operations soared 688.9% — and 2024, when it sank 272.46%.
- Barinthus Biotherapeutics' Cash from Operations stood at 11343000.0 in 2022, then sank by 72.82% to 19603000.0 in 2023, then surged by 166.76% to 13086000.0 in 2024, then slumped by 132.42% to 4242000.0 in 2025, then gained by 20.65% to 3366000.0 in 2026.
- The last three Cash from Operations figures came in at 3366000.0 (Q1 2026), 4242000.0 (Q4 2025), and 10726000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -2.49 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Barinthus Biotherapeutics | 27.08 Mn | -40.03 Mn | - | -3.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.37 Mn |
| Mar 31, 2026 | -3.37 Mn |
| Dec 31, 2025 | -4.24 Mn |
| Dec 31, 2025 | -4.24 Mn |
| Sep 30, 2025 | -10.73 Mn |
| Sep 30, 2025 | -10.73 Mn |
| Jun 30, 2025 | -18.11 Mn |
| Jun 30, 2025 | -18.11 Mn |
| Mar 31, 2025 | -14.90 Mn |
| Mar 31, 2025 | -14.90 Mn |
| Dec 31, 2024 | 13.09 Mn |
| Dec 31, 2024 | 13.09 Mn |
| Sep 30, 2024 | -18.20 Mn |
| Sep 30, 2024 | -18.20 Mn |
| Jun 30, 2024 | -12.01 Mn |
| Jun 30, 2024 | -12.01 Mn |
| Mar 31, 2024 | -11.82 Mn |
| Mar 31, 2024 | -11.82 Mn |
| Dec 31, 2023 | -19.60 Mn |
| Dec 31, 2023 | -19.60 Mn |